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doi:10.1016/j.ejvs.2009.01.020Abstract Object: Abdominal aortic aneurysm (AAA) pathogenesis remains poorly understood.
This study investigated the gene expression profile of peripheral blood from patients with AAA
using microarray technology.
Methods and results: We determined gene expression profiles in pooled RNA from 10 AAA
patients and 10 matched controls with arrays representing 14,000 transcripts. Microarray data
for selected genes were confirmed by real-time PCR in two different AAA (nZ 36) and control
(nZ 36) populations and integrated with biochemical data. We identified 91 genes which were
differentially expressed in AAA patients. Gene Ontology analysis indicated a significant alter-
ation of oxygen transport (increased hemoglobin gene expression) and lipid metabolism
[including monoglyceride lipase and low density lipoprotein receptor-related protein 5
(LRP5) gene]. LRP5 expression was associated inversely with serum lipoprotein(a) [Lp(a)]
concentration.
Conclusions: Increased expression of hemoglobin chain genes as well as of genes involved in
erythrocyte mechanical stability were observed in the AAA RNA pools. The association between
low levels of LRP5 gene expression and increased levels of Lp(a) in AAA patients suggests
a potential role of LRP5 in Lp(a) catabolism. Our data underline the power of microarrays in
identifying further molecular perturbations associated with AAA.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.949420; fax:þ390557949418.
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The prevalence of abdominal aortic aneurysm (AAA) varies
ranging from 4.1% to 11.5% in European men.1 This disorder
is characterized by localized structural deterioration of thed by Elsevier Ltd. All rights reserved.
Abdominal Aortic Aneurysm: Gene Expression Profile 105aortic wall, leading to progressive dilatation and eventual
aortic rupture.2 Rupture of AAA is responsible for 1.5% of
the total mortality in males over 55 years of age.3
There are several factors such as smoking, hypertension,
hypercholesterolemia and male sex,4 which are well known
risk factors for the development of AAA.5e7 However,
better understanding of molecular mechanisms is an
important step toward clarification of the pathophysiology,
identification of genetic and molecular biomarkers and
development of new therapeutic strategies for AAA.
Gene expression profiling studies by microarray tech-
nologies are particularly appropriate to investigate and
create working hypotheses to understand the pathophysi-
ology of complex genetic tracts such as AAA. Previous
microarray studies of AAA utilized RNA derived from aortic
tissue samples.8e11 The use of tissue samples has several
disadvantages, including the difficulty of obtaining control
samples and bias introduced by use of normal specimens
from non-age-matched cadavers, organ-transplant donors
or patients with different diseases. Peripheral blood is
a complex fluid with a high cellular turnover rate that
provides physiological connectivity between tissues. Envi-
ronmental or disease perturbations in the body may leave
molecular signatures detectable by analyzing blood-derived
RNA.12,13 Most importantly, since blood samples can be
obtained readily and with little discomfort to patients,
biomarkers derived from blood RNA provide an easier
integration to clinical and imaging data for the diagnosis
and prognosis of AAA.
This study aimed to investigate the gene expression
profile of venous whole peripheral blood obtained from AAA
patients by using microarray technology to provide insight
into systemic pathophysiological processes involved in this
disease.
Materials and Methods
Subjects
We enrolled 46 patients with AAA referred to the Unit of
Vascular Surgery of the University of Florence. Familial and
inflammatory AAAs were excluded from the study. Familial
AAA was defined when one or more first-degree family
members were affected by AAA, whereas inflammatory AAA
was diagnosed on the basis of preoperative features
(lumbar or abdominal pain, elevated erythrocyte sedi-
mentation rate, and weight loss) and operative appearance
(presence of extensive perianeurysmal and retroperitoneal
fibrosis and dense adhesions to adjacent abdominal
organs). A group of 46 healthy subjects matched for age and
gender were used as controls. All controls had a negative
history of vascular diseases. All subjects underwent duplex
scanning examination using an Acuson Sequoia Color Duplex
System (Mountain View, CA). Ultrasound scanning exami-
nation was then confirmed in all patients with high reso-
lution computed tomography scan examination (Siemens
CT, Somatom HIQ Type 600). The aneurysm diameter
recorded was the largest measured in either the anteriore
posterior or the transverse plane. All AAA patients had
a maximum aortic diameter larger than 5 cm. Digital
subtraction angiography was performed only in patientswith concomitant peripheral arterial disease. Patients were
considered to have hypertension if were taking antihyper-
tensive drugs or in the presence of systolic pressure
140 mmHg and/or diastolic pressure 90 mmHg. Dyslipi-
demia was defined in the presence of total cholesterol
levels >4.9 mmol/l and/or LDL-cholesterol >3.0 mmol/l
and/or HDL <1 mmol/l and/or triglyceride levels
>1.7 mmol/l according to the Third Report of the National
Cholesterol Education Program. Patients were considered
to have diabetes if were taking hypoglycaemic drugs or in
the presence of fasting glucose levels 7.0 mmol/l on at
least two separate occasions.
To assess the presence of other atherosclerotic locali-
zations, all subjects underwent clinical and diagnostic
examination (electrocardiography, echocardiography,
duplex scanning of carotid arteries and ankle/brachial
pressure index evaluation). Severe carotid stenosis was
defined according to the North American Symptomatic
Carotid Evaluation Trial criteria.14
Peripheral arterial disease was documented as present if
ankle/brachial pressure index was less than 0.9. The study
was approved by the local Ethical Committee and written
consent was obtained from each enrolled subject.
Haematological parameters
Blood samples were taken from all subjects for blood
counts [red blood cells (RBC), white blood cells (WBC),
hemoglobin (Hb), hematocrit (Hct), reticulocytes] and for
serum erythropoietin (EPO) level measurement. The RBC,
WBC and reticulocytes count, and Hb and Hct were evalu-
ated using an automated counter, while EPO was deter-
mined by DSL1100 Erythropoietin RIA (Diagnostic Systems
Laboratories, Texas, USA). Lipoprotein(a) [Lp(a)] concen-
trations were determined on serum by an ELISA method
[Mercodia Apo(a), Mercodia AB, Uppsala, Sweden]. We
considered levels of Lp(a) determining an increased risk for
atherothrombosis as plasma levels >300 mg/L.15
Total RNA preparation
Total RNA was extracted from venous peripheral blood of 46
AAA patients and 46 controls using PAXgene Blood RNA Kit
(Qiagen, Germany). We integrated the RNA extraction
protocol with a DNAse treatment to remove contaminating
genomic DNA. Moreover, the absence of contaminating
genomic DNA was confirmed by PCR analysis with specific
primers. The quality of the RNA was analyzed with the 2100
Bioanalyzer (Agilent, CA, USA). RNA with a RNA Integrity
Number (RIN) 6.5 was used for microarray and real-time-
PCR experiments. Equal quantities of total RNA from 10 AAA
patients and 10 age- and gender-matched controls were
pooled in 4 different pools according to the experimental
design reported below.
Experimental design and microarray gene
expression analysis
We established two different pools for 10 AAA patients
(nZ 5 patients in pool A and nZ 5 patients in pool B) and
two different pools for 10 healthy subjects (nZ 5 controls
106 B. Giusti et al.in pool C and nZ 5 controls in pool D). The demographic
and clinical characteristics of each pool are provided as
supplemental data (Table A). Two replicates with Cy3 and
Cy5 fluorochrome inversion (dye swap) of the two micro-
array experiments were performed.
Experiment 1:
AAA pool A Cy3 labelled vs control pool C Cy5 labelled
AAA pool A Cy5 labelled vs control pool C Cy3 labelled
(dye swap);
Experiment 2:
AAA pool B Cy3 labelled vs control pool D Cy5 labelled
AAA pool B Cy5 labelled vs control pool D Cy3 labelled
(dye swap).
Microarray experiments were performed as described
previously.16,17 We used arrays representing 14,000 genes
(70mer oligonucleotides; Human AROS v1.1, Operon Tech-
nologies, CA, USA).
Image processing and statistical analysis
Scanned images were processed using the GenePix Pro 4.1
software (Axon Instruments, CA, USA). For each microarray,
we performed a local intensity-dependent normalization.18
Normalization procedure was done by Statistical Micro-
array Analysis package (http://stat-www.berkeley.edu/
users/terry/zarray/Software/smacode.html).
Then data were analyzed by ‘‘Significant Analysis of
Microarray’’ (SAM) algorithm.19 In SAM analysis we choose
a delta value of 0.8 that allowed us to identify 91 differ-
entially expressed genes with a false discovery rate (FDR) of
2.2%. The full data set is available at ArrayExpress (E-mexp-
1346 in http://www.ebi.ac.uk/microarray-as/ae/browse.
html).
Gene Ontology analysis
To analyze the involvement of differentially expressed
genes in different biological functional groups, all the
genes present on the microarray were annotated for their
role in biological processes. In our study we used one of the
three ontologies produced by the Gene Ontology (GO)
consortium, the biological process ontology.20,21 The term
‘‘biological process’’ should be interpreted as a biological
function to which the gene product contributes. The actual
mapping of genes to GO terms is provided by the Gene
Ontology Annotation Database. The mappings were down-
loaded from ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/
gene2go.gz. Briefly, given a set of genes and one
ontology, we first found the set of all unique GO terms
within the ontology that were associated with one or more
of the genes of interest. Next, we determined how many of
the differentially expressed genes were annotated at each
term and how many of the genes that were assessed (all the
genes represented on the microarray) were annotated at
the term. The test evaluated if there were more genes of
interest at the term than would be expected by chance
alone. Due to the small number of genes in some cate-
gories, two-sided Fisher’s exact test was applied. The
statistical analyses were implemented in the R environment
using Bioconductor packages.Real-time PCR based gene expression analysis
In order to confirm results obtained by microarray analysis,
the expression of ten selected genes was also measured by
real-time (RT)-PCR, both in subjects included in pools and
in 36 additional patients and controls. To quantify the
transcribed low density lipoprotein receptor-related
protein 5 (LRP5), basigin (BSG), hemoglobin alpha 2 (HBA2),
hemoglobin delta (HBD), hemoglobin epsilon 1 (HBE1),
hemoglobin theta 1 (HBQ1), hemoglobin beta (HBB),
hemoglobin gamma (HBG), aminolevulinate delta synthase
2 (ALAS2), dematin (EPB49), glycophorin c (GYPC ) and
stomatin (STOM ) genes, we performed TaqMan RT-PCR on
an ABI Prism 7700 instrument (Applied Biosystems, CA,
USA). We used TaqMan pre-developed assays (Applied Bio-
systems, CA, USA) (Supplementary Data). Reactions were
performed in duplicate with 50 ng cDNA. The ‘‘delta-delta
Ct method’’ was used for comparing relative gene expres-
sion results (PE Applied Biosystems, PerkineElmer, CA). DCt
values of the samples were determined by subtracting the
average of the duplicate Ct values of the target genes from
the average of the duplicate Ct values of the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH ) gene (refer-
ence). The relative gene expression levels were determined
by subtracting the average DCt value of the target from the
average DCt value of the calibrator. The amount of target
(expressed as fold-change), standardised to an endogenous
reference and relative to a calibrator, was given by 2DDCt.
Statistical analysis
Statistical analyses were carried out using statistical tests
as implemented in SPSS software (v.11.5). All values were
expressed as median and range. When comparing groups,
statistical significance was determined by using non-para-
metric ManneWhitney test. In order to test correlation
between different parameters the Spearman’s correlation
was used. Multivariate logistic regression analysis was used
to evaluate the independent association of different gene
expressions with the AAA disease [odds ratio (OR) and 95%
confidence interval (CI)]. A p value less than 0.05 was
considered statistically significant.
Results
Demographic and clinical characteristics
In Table 1 demographic and clinical characteristics of AAA
patients and healthy subjects were reported. AAA patients
are characterized by high prevalence of both cardiovas-
cular risk factors and chronic obstructive pulmonary
disease (COPD, 58.7%).
Gene expression profile by microarray technology
of peripheral venous whole blood
Of the 14,000 transcripts represented on our arrays, after
data processing and application of the filtering criteria, the
analyzed transcripts numbered 3981.
The SAM analysis showed 91 genes differentially
expressed in venous peripheral whole blood of AAA patients
Table 1 Demographic and clinical characteristics of AAA patients and controls enrolled in pools used for gene expression
profiling and for validation analyses on a second larger population.
AAA in pool
(NZ 10)
CTR in pool
(NZ 10)
p AAA patients
(NZ 36)
CTR subjects
(NZ 36)
p
Age 68 (60e82) 66 (52e85) e 69 (55e84) 70 (52e86) e
Sex (male) N (%) 8 (80) 8 (80) e 32 (88.9) 32 (88.9) e
Smoking N (%) 8 (80) 2 (20) 0.012 24 (66.6) 12 (33.3) 0.005
Diabetes N (%) 1 (10) 0 0.499 3 (8.3) 0 0.119
Hypertension N (%) 6 (60) 2 (20) 0.085 27 (75.0) 8 (22.2) 7.46 106
Dyslipidemia N (%) 7 (70) 1 (10) 0.009 25 (69.4) 2 (5.5) 2.14 108
CAD N (%) 1 (10) 0 0.499 13 (36.1) 0 6.80 105
CAS N (%) 1 (10) 0 0.499 7 (19.4) 0 0.005
PAD N (%) 1 (10) 0 0.499 8 (22.2) 0 0.003
COPD N (%) 6 (60) 0 0.005 21 (58.3) 0 5.18 108
AAAZ abdominal aortic aneurysm; CTRZ control; CADZ coronary artery disease; CASZ carotid artery stenosis; PADZ peripheral
obstructive artery disease; COPDZ chronic obstructive pulmonary disease.
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expression and 15/91 genes with decreased expression
(Table 2).
Gene Ontology analysis of differentially expressed
genes in AAA patients
According to GO analysis adjusted by using the FDR multiple
testing correction, we observed 3 significant biological
processes (terms) associated with genes differentially
expressed in AAA patients (Table 3). Statistically significant
enriched GO biological processes were ‘‘oxygen transport’’,
‘‘positive regulation of protein kinase activity’’, and ‘‘lipid
metabolic process’’.
We observed that, apart from the 4 genes coding for
erythrocyte hemoglobin chains associated to the GO term
‘‘oxygen transport’’, other erythrocyte genes or genes
involved in erythropoiesis showed increased expression in
AAA patients including EPB49, GYPC, STOM, flotillin 1
(FLOT1), solute carrier family 25-member 37 (SLC25A37)
and ALAS2.
Six genes differentially expressed in AAA patients were
associated with the GO term ‘‘lipid metabolic process’’: 5
out of 6 with increased expression [acyl-Coenzyme A
dehydrogenase C-2 to C-3 short chain, ACADS; cell death-
inducing DFFA-like effector a, CIDEA; monoglyceride lipase,
MGLL; adiponectin receptor 1, ADIPOR1; hydroxysteroid
(17-beta) dehydrogenase 14, HSD17B14], and 1 out of 6 with
decreased expression (LRP5).
Microarray data validation by RT-PCR
To validate microarray data, mRNA expression of 12 genes
was independently examined by real-time RT-PCR. We
selected 5 genes involved in oxygen transport (HBA2, HBD,
HBE1, HBQ1, ALAS2); 3 genes coding for cellular compo-
nents of erythrocytes which play a role in the regulation of
the mechanical stability of red cells (EPB49, a membrane
skeleton protein; GYPC, a transmembrane glycoprotein;
STOM, a cytoskeleton component); 1 gene associated with
the ‘‘lipid metabolic process’’ (LRP5); 1 gene known to be
an inducer of metalloproteinases (BSG), and 2 genescoding for the other two hemoglobin chains (HBB, HBG),
which we could not analyze by microarray analysis (due to
a failure in oligonucleotide deposition during array
construction). We evaluated these genes in the total RNAs
of patients and controls used for comparative microarray
experiments and in two different larger populations of AAA
patients and controls (Table 4). The correlation between
gene expression evaluated by microarray experiments and
RT-PCR in validated genes narrowly failed to achieve
statistical significance (Spearman’s correlation 0.62,
pZ 0.057).
RT-PCR analysis on subjects included in the pools
confirmed data obtained by microarray for all the investi-
gated genes (Table 4).
Analysis of further, separate AAA patients and controls
showed increased expression of HBB, HBD, HBQ1, ALAS2,
BSG and GYPC genes and decreased expression of LRP5 gene
in AAA patients with respect to controls (Table 4).
Multivariate logistic regression analysis with AAA as
dependent variable and expression of validated genes, and
traditional cardiovascular risk factors (age, gender, hyper-
tension, dyslipidemia, smoking habit) and COPD as inde-
pendent variables, was performed. HBB, HBQ1, HBD and
LRP5 gene expression levels were significantly and inde-
pendently associated with AAA [2.18 (95%CI 1.09e4.37),
pZ 0.028; 3.12 (95%CI 1.14e8.55), pZ 0.026; 2.19 (95%CI
1.22e3.95), pZ 0.009; 0.15 (95%CI 0.02e0.90), pZ 0.039,
respectively]. Association of ALAS2 and BSG gene expres-
sion with AAA disease did not reach statistical significance
[1.90 (95%CI 0.96e3.76), pZ 0.065 and 2.33 (95%CI 0.97e
5.59), pZ 0.059, respectively].
Relationship between LRP5 gene expression and
Lp(a) serum levels in AAA patients
Due to the possible role of LRPs protein in the catabolism of
Lp(a), we investigated the relationship between LRP5
expression and serum Lp(a) concentrations. Lp(a) concen-
trations in AAA patients (median 248 mg/L, interquartile
range 78e416 mg/L) were significantly higher than in
controls (median 105 mg/L, interquartile range 58e
203 mg/L), pZ 0.049. Serum Lp(a) concentration was
Table 2 Genes differentially expressed in the blood of AAA patients.
Gene name Symbol Accession No GeneID d
Genes with increased expression in AAA patients
Hemoglobin, alpha 2 (*) HBA2 V00488 3040 5.30
Monoglyceride lipase MGLL U67963 11343 4.79
Guanylate kinase 1 GUK1 L76200 2987 3.52
Hemoglobin, epsilon 1 (*) HBE1 NM_005330 3046 3.49
Cell death-inducing DFFA-like effector a CIDEA AF041378 1149 3.34
ATPase, Naþ/Kþ transporting, alpha polypeptide-like 1 ATP12A L42563 479 3.21
PDZ domain containing RING finger 4 PDZRN4 AL133067 29951 2.92
CGI-69 protein CGI-69 NM_016016 51629 2.88
Hemoglobin, delta (*) HBD V00505 3045 2.78
Defensin, alpha 1, myeloid-related sequence DEFA1 M26602 1667 2.48
Hemoglobin, theta 1 (*) HBQ1 NM_005331 3049 2.44
Zinc finger and BTB domain containing 39 ZBTB39 AB002350 9880 2.44
Immunoglobulin lambda joining 3 IGLJ3 X57812 28831 2.42
Makorin, ring finger protein, 1 MKRN1 NM_013446 23608 2.40
Cyclin B3 CCNB3 AL137550 85417 2.36
Zinc finger protein 193 ZNF193 U62392 148022 2.29
Toll-like receptor adaptor molecule 1 TICAM1 AF070530 7746 2.29
SEC24 (Saccharomyces cerevisiae) related gene family, member D SEC24D AB018298 9871 2.27
Serologically defined colon cancer antigen 1 SDCCAG1 NM_004713 9147 2.24
Ubiquitin-conjugating enzyme E2M (homologous to yeast UBC12) UBE2M AF075599 9040 2.19
Free fatty acid receptor 2 FFAR2 AF024690 2867 2.18
Glycophorin C (Gerbich blood group) (*) GYPC NM_002101 2995 2.16
Protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting1 PIN1 U49070 5300 2.14
Three prime repair exonuclease 2 TREX2 AF151107 11219 2.12
MTERF domain containing 2 MTERFD2 BX648184 130916 2.07
Flotillin 1 FLOT1 AF089750 10211 2.01
Interleukin 1 receptor accessory protein-like 1 IL1RAPL1 AJ243874 11141 2.00
Chorionic somatomammotropin hormone-like 1 CSHL1 BC029365 1428 1.99
Solute carrier family 25, member 37 SLC25A37 AF223466 1444 1.99
Glioma-associated oncogene homolog (zinc finger protein) GLI1 X07384 2735 1.99
Crystallin, mu CRYM L02950 51312 1.99
Nucleoporin 88 kD NUP88 Y08612 2039 1.93
Erythrocyte membrane protein band 4.9 (dematin) (*) EPB49 U28389 4927 1.93
Splicing factor, arginine/serine-rich (transformer 2 Drosophila homolog) 10 SFRS10 U68063 6434 1.91
ATG5 autophagy related 5 homolog (S. cerevisiae) ATG5 Y11588 9474 1.90
Chromosome 20 open reading frame 29 C20orf29 AK002030 55317 1.90
S100 calcium-binding protein A6 (calcyclin) S100A6 J02763 6277 1.90
Lipocalin 2 (oncogene 24p3) LCN2 X99133 3934 1.89
Potassium channel tetramerisation domain containing 12 KCTD12 AF359381 115207 1.87
Small EDRK-rich factor 2 SERF2 NM_005770 10169 1.86
Platelet factor 4 variant 1 PF4V1 M26167 5197 1.85
Ribosomal protein L18 RPL18 L11566 6141 1.84
Erythrocyte membrane protein band 7.2 (stomatin) (*) STOM U33931 2040 1.84
Paralemmin PALM Y16270 5064 1.80
Myelin transcription factor 2 MYT2 AF006822 8827 1.79
Adiponectin receptor 1 ADIPOR1 AK001484 51094 1.78
Interferon, alpha 13 IFNA13 BC069427 3447 1.78
SMC (mouse) homolog, X chromosome SMCX L25270 8242 1.77
Nuclear factor I/B NFIB U85193 4781 1.76
Similar to HSPC323 LOC284422 AF161441 284422 1.75
Phospholipase A2, group IB (pancreas) PLA2G1B M21054 5319 1.75
Zinc finger protein 145 (Kruppel-like, expressed in promyelocytic leucemia) ZBTB16 Z19002 28904 1.73
Immunoglobulin kappa variable 1D-8 IGKV1D-8 M63438 7704 1.73
Potassium voltage-gated channel, shaker-related subfamily, member 3 KCNA3 M85217 51171 1.72
Hydroxysteroid (17-beta) dehydrogenase 14 HSD17B14 NM_016246 3738 1.72
Mitogen-activated protein kinase kinase 3 MAP2K3 D87116 509 1.71
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Table 2 (continued )
Gene name Symbol Accession No GeneID d
ATP synthase, Hþ transporting, mitochondrial F1 complex, gamma polypeptide 1 ATP5C1 D16562 5606 1.71
Translocase of inner mitochondrial membrane 8 (yeast) homolog A TIMM8A U66035 1678 1.71
HUS1 (Saccharomyces pombe) checkpoint homolog HUS1 AF076844 3364 1.69
Transcription elongation factor A (SII), 2 TCEA2 D50495 6919 1.69
Tumor necrosis factor type 1 receptor-associated protein TRAP1 NM_016292 10131 1.69
Karyopherin alpha 4 (importin alpha 3) KPNA4 AB002533 3840 1.68
Chaperonin containing TCP1, subunit 6A (zeta 1) CCT6A L27706 908 1.67
Immunoglobulin lambda variable 1-47 IGLV1-47 Z73663 28822 1.67
MutL homolog 3 (Escherichia coli) MLH3 AB039667 50801 1.67
Potassium inwardly-rectifying channel, subfamily K, member 4 KCNK4 AF247042 27030 1.67
RNA-binding protein S1, serine-rich domain RNPS1 L37368 10921 1.66
Zinc finger protein 384 ZNF384 U80738 7177 1.66
Tryptase, alpha TPSAB1 M30038 171017 1.66
Ring finger protein 44 RNF44 AB029023 51374 1.65
Apoptosis related protein APR-3 APR3 NM_016085 22838 1.65
Basigin (*) BSG X64364 35 1.64
Aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia) (*) ALAS2 X60364 212 1.64
Acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain ACADS Z80345 682 1.64
Sarcolipin SLN U96094 6588 1.63
Myogenic factor 6 (herculin) MYF6 X52011 4618 1.62
Genes with decreased expression in AAA patients
Eukaryotic translation elongation factor 1 beta 2 EEF1B2 X60489 1933 1.97
Regulator of G-protein signaling 2, 24 kD RGS2 L13463 5997 1.97
Protein tyrosine phosphatase, receptor type, c polypeptide PTPRC Y00062 5788 2.04
ARP2 (actin-related protein 2, yeast) homolog ACTR2 AF006082 10097 2.17
Similar to chloride intracellular channel protein 1 (Nuclear chloride ion channel 27)
(NCC27) (p64 CLCP) (Chloride channel ABP)
LOC390363 XM_495936 390363 2.28
High-mobility group (nonhistone chromosomal) protein 1 like 10 HMG1L5 L08048 10354 2.37
Receptor-associated protein of the synapse, 43 kD RAPSN Z33905 5913 2.46
Chromosome 12 open reading frame 35 C12orf35 AK000703 55196 2.59
Homo sapiens Bruton’s tyrosine kinase BTK U78027 695 2.76
Ribosomal protein L17 RPL17 X53777 6139 2.85
Complement factor H-related 4 CFHR4 X98337 10877 2.94
Immunoglobulin superfamily containing leucine-rich repeat ISLR AB024536 3671 3.44
Low density lipoprotein receptor-related protein 5 (*) LRP5 AF077820 4041 3.46
Apoptosis antagonizing transcription factor AATF AJ249940 26574 4.30
Anti-Mullerian hormone receptor, type II AMHR2 U29700 269 5.62
d-valueZ significance analysis of microarrays (SAM) t-statistic; (*)Z genes validated by real-time PCR.
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cient 0.411, pZ 0.00034; Spearman’s coefficient after
removal of the outliers (>1000 mg/L) 0.339, pZ 0.004]
(Fig. 1). AAA patients with Lp(a) levels higher than 300 mg/
L had reduced LRP5 expression levels versus patients with
Lp(a) levels lower than 300 mg/L (pZ 0.050).Table 3 List of all the Gene Ontology (GO) significant terms (b
GO ID p value N n GO Term
GO:0015671 <0.0001 9 4 oxygen tran
GO:0045860 0.029 3 2 positive reg
of protein k
GO:0006629 0.049 190 6 lipid metab
n, number of differentially expressed genes annotated to the GO term
GO term; p values were adjusted by using the false discovery rate (FHaematological parameters in AAA patients and
controls
In order to investigate the possible mechanisms and/or
effects of expression changes in erythrocyte genes, we
evaluated some haematological parameters in AAA patientsiological processes) in AAA patients.
Genes
sport HBA2([), HBD([), HBE1([), HBQ1([)
ulation
inase activity
MAP2K3([), PTPRC(Y)
olic process ACADS([), CIDEA([), LRP5(Y), MGLL([),
ADIPOR1([), HSD17B14([)
; N, number of genes represented on the array annotated to the
DR) multiple testing correction.
Table 4 Fold-change of increase or decrease expression of genes analyzed by RT-PCR in AAA patients versus controls.
Gene AAA patients and controls in pools
nZ 10 AAA patients vs nZ 10 controls
AAA patients and controls
nZ 36 AAA patients vs nZ 36 controls
Fold-change (range) p M Fold-change (range) p
LRP5 0.29 (0.21e0.42) 0.0008 1.58 0.63 (0.29e1.37) 0.025
HBA2 4.82 (4.50e5.17) 0.001 2.93 1.15 (0.72e1.84) 0.537
HBB 6.82 (5.94e7.83) 0.00001 e 4.72 (0.47e47.50) 7.53 10L5
HBD 6.54 (5.50e7.78) 0.00005 2.41 12.21 (2.19e68.12) 3.03 10L5
HBG 1.36 (1.18e1.56) 0.0008 e 2.23 (0.55e9.06) 0.188
HBQ1 9.99 (9.00e11.08) 0.0001 2.19 2.38 (0.29e19.16) 0.003
HBE1 3.55 (2.89e4.38) 0.0009 2.65 1.44 (0.54e3.86) 0.178
GYPC 5.73 (4.50e7.31) 0.0006 1.87 2.20 (0.89e5.46) 0.025
STOM 2.25 (1.89e2.67) 0.001 1.29 1.17 (0.65e2.11) 0.390
EPB49 5.39 (5.20e5.58) 0.0009 2.11 0.89 (0.36e1.90) 0.539
ALAS2 3.60 (2.52e4.37) 0.0004 0.89 2.69 (0.63e11.52) 2.93 10L4
BSG 1.85 (1.29e2.06) 0.0008 1.85 2.06 (0.61e6.90) 8.23 10L4
RT-PCRZ Real-Time Polymerase Chain Reaction, mean of the M valuesZmean of log2 Cy5/Cy3 fluorescence intensities for each gene;
non-parametric ManneWhitney test was used for determining statistical significance.
Table 5 Haematological parameters in AAA patients and
110 B. Giusti et al.and controls (Table 5). AAA patients had significantly higher
Hct values and WBC counts. No differences were observed
for reticulocyte counts.
Discussion
In this study, we analyzed gene expression profiles of
venous peripheral whole blood of AAA patients. Based on
Gene Ontology and other classification criteria, we found
that AAA patients differentially express a variety of tran-
scripts involved in oxygen transport, regulation of the
mechanical stability of the red cells and lipid metabolism.
The decreased expression of LRP5 gene was associated with
increased levels of Lp(a), a known atherothrombotic risk
factor, previously associated with AAA.15,22 Moreover,
a large panel of erythrocyte genes was differentially
expressed in AAA patients.
Even though previous microarray studies of AAA focused
on gene expression profile from aortic tissue samples,8e110 200 400 600 800 900 1200 1500
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Figure 1 Correlation between Lp(a) serum concentrations
and LRP5 gene expression in AAA patients and controls.some genes appear to be differentially expressed both in
tissue11 and peripheral blood, including LRP5, mitogen-
activated protein kinase kinase 3 (MAP2K3), EPB49, STOM,
regulator of G-protein signaling 2 (RGS2) (see also supple-
mentary data Table C). Further data are required to
investigate the potential role of these genes in the AAA
pathophysiology.
Our data, showing decreased LRP5 gene expression in
the peripheral blood cells of AAA patients, are echoed in
the microarray profiling of the aortic wall of AAA patients
reported in a previous study.11 The LRP5 gene is involved in
bone metabolism23,24 as well as lipoprotein and glucose
metabolism.25 Experimental studies have shown that
apoE;Lrp5 double knockout mice developed multiple
atheromatous aortic lesions manifesting a hump structure,
which were associated with cholesterol deposits, fibrosis,controls.
Haematological
parameters
Controls
(NZ 36)
Patients
(NZ 36)
p
White Blood
Cells (103/mL)
5.6 (3.0e8.3) 7.0 (3.5e11.6) 0.034
Red Blood
Cells (106/mL)
4.5 (3.9e5.3) 4.7 (3.5e5.7) 0.171
Hemoglobin
(g/dL)
13.9 (11.8e15.9) 14.4 (11.0e16.8) 0.331
Hematocrit
(%)
39.8 (34.7e44.5) 42.7 (35.2e51.7) 0.033
Reticulocytes
(%)
0.89 (0.46e1.5) 0.92 (0.54e2.14) 0.986
Erythropoietin
(mU/mL)
11.5 (7.6e24.1) 13.2 (5.6e30.5) 0.224
Values of the different haematological parameters are
expressed as median and range. Non-parametric ManneWhitney
test was used for determining statistical significance. A p value
less than 0.05 was considered statistically significant.
Abdominal Aortic Aneurysm: Gene Expression Profile 111and elastolysis, some even showing the destruction of
internal elastic lamina and the degenerative changes in
aortic smooth muscle.26
We demonstrated, for the first time, an association
between decreased expression levels of LRP5 gene and
increased levels of Lp(a) in AAA patients, which suggests
a potential role of LRP5 in Lp(a) catabolism. Several studies
have demonstrated that high serum Lp(a) concentrations
play a role in the genesis of systemic atherosclerosis,
thrombosis, and related disorders.27 The mechanisms
implicated in the atherogenicity of Lp(a) include the
tendency to self-aggregate and precipitate, binding to
glycosaminoglycans and other structures in the vascular
wall, impaired fibrinolysis due to its structural homology
with plasminogen, regulation of synthesis of plasminogen
activator inhibitor-1 and the induction of smooth muscle
cell proliferation.28
Our data highlight the role of the alteration of a large
number of erythroblast genes involved in oxygen transport
and red cell structure stability. Of particular interest was
the finding of an increased expression in AAA patients of
HBQ1 gene, which encodes the embryonic theta hemoglobin
chain. This might suggest a switch toward the reactivation,
in AAA patients, of the expression of genes not normally
expressed in adult humans. We also observed increased
expression of ALAS2. This mitochondrial enzyme catalyses
the first step in the haem biosynthetic pathway. Murine
erythroleukemia cells, exposed to hypoxia, showed an up to
3-fold increased expression of ALAS2 mRNA levels and an
increase in cellular haem content.29 The increased expres-
sion of hemoglobin genes could represent a secondary
response to chronic hypoxia and oxidative stress. In addi-
tion, the increased expression of structural erythrocyte
genes, such as GYPC, might play a role in the adaptative
processes of the red cells to chronic hypoxia and haemo-
dynamic stress. Haematological data, in particular the
higher hematocrit in AAA patients lends support to the
hypothesis that increased expression of red cell genes is, at
least in part, a response to chronic hypoxia.
Other genes identified in the microarray analysis also
may be relevant to the pathophysiology of AAA. Of partic-
ular interest is the BSG gene coding for basigin or EMMPRIN,
a 58 kDa membrane glycoprotein member of the immuno-
globulin superfamily, which had increased gene expression
in our AAA patients. This may be the first observation that
this important inducer of several metalloproteinases
(MMPs) and in particular of MMP9 is expressed in peripheral
blood cells.
Our study has several limitations, in particular the
variation in number and types of the different cell pop-
ulations in the samples30 as well as confounding factors
(recognised and unrecognised) resulting from the different
demographic profiles of AAA patients and controls. For
example, due to the higher prevalence of traditional
cardiovascular risk factors and other clinical manifestations
of atherosclerosis in our AAA patients (CAD, CAS and PAD),
we cannot confirm that the differentially expressed genes
identify biomarkers of AAA versus atherosclerosis. In this
respect, further gene expression profiling studies, enrolling
patients suffering from atherosclerotic lesions in different
localization such as carotid artery disease or peripheral
arterial disease, might provide further information.In conclusion, gene profiling of peripheral whole venous
blood cells may provide an interesting way to explore the
complex pathophysiology of AAA. Our findings suggest that
the decreased expression of LRP5 gene and the increased
expression of erythrocyte genes might be potential
molecular alterations characterising aneurysmal disease.
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